Design, synthesis, and biological evaluation of highly potent small molecule-peptide conjugates as new HIV-1 fusion inhibitors

Journal of Medicinal Chemistry

Volumn 56, Issue 6, 2013, Pages 2527-2539

  Wang, Chao ^a   Shi, Weiguo ^a   Cai, Lifeng ^a   Lu, Lu ^b   Wang, Qian ^b   Zhang, Tianhong ^a   Li, Jinglai ^a   Zhang, Zhenqing ^a   Wang, Kun ^a   Xu, Liang ^a   Jiang, Xifeng ^a   Jiang, Shibo ^b   Liu, Keliang ^a  

^a BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

C 34; ENFUVIRTIDE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; N(3 CARBOXY 4 HYDROXYPHENYL) 2,5 DIMETHYLPYRROLE DERIVATIVE; N(4 CARBOXY 3 HYDROXYPHENYL) 2,5 DIMETHYLPYRROLE DERIVATIVE; PROTEINASE K; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CELL ASSAY; CELL FUSION; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENTIATION; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; STRUCTURE ACTIVITY RELATION; VIRUS STRAIN;

AMINO ACID SEQUENCE; CELL LINE; CHEMISTRY TECHNIQUES, SYNTHETIC; DRUG DESIGN; DRUG RESISTANCE, VIRAL; ENDOPEPTIDASE K; HIV ENVELOPE PROTEIN GP41; HIV-1; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN STRUCTURE, SECONDARY; REPETITIVE SEQUENCES, AMINO ACID; SMALL MOLECULE LIBRARIES; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 84875704905     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3018964     Document Type: Article

References (41)

1. Chan, D. C.; Fass, D.; Berger, J. M.; Kim, P. S. Core structure of gp41 from the HIV envelope glycoprotein Cell 1997, 89, 263-273
2. Chan, D. C.; Kim, P. S. HIV entry and its inhibition Cell 1998, 93, 681-684
3. Ashkenazi, A.; Shai, Y. Insights into the mechanism of HIV-1 envelope induced membrane fusion as revealed by its inhibitory peptides Eur. Biophys. J. 2011, 40 (4) 349-357
4. Cai, L.; Jiang, S. Development of peptide and small-molecule HIV-1 fusion inhibitors that target gp41 ChemMedChem 2010, 5 (11) 1813-1824
5. Naider, F.; Anglister, J. Peptides in the treatment of AIDS Curr. Opin. Struct. Biol. 2009, 19, 473-482
6. Gallo, S. A.; Puri, A.; Blumenthal, R. HIV-1 gp41 six-helix bundle formation occurs rapidly after the engagement of gp120 by CXCR4 in the HIV-1 Env-mediated fusion process Biochemistry (Moscow) 2001, 40, 12231-12236
7. Liu, S.; Wu, S.; Jiang, S. HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds Curr. Pharm. Des. 2007, 13 (2) 143-162
8. Pan, C.; Liu, S.; Jiang, S. HIV-1 gp41 fusion intermediate: a target for HIV therapeutics J. Formosan Med. Assoc. 2010, 109 (2) 94-105
9. Liu, S.; Zhao, Q.; Jiang, S. Determination of the HIV-1 gp41 fusogenic core conformation modeled by synthetic peptides: applicable for identification of HIV-1 fusion inhibitors Peptides 2003, 24 (9) 1303-1313
10. Jiang, S.; Zhao, Q.; Debnath, A. K. Peptide and non-peptide HIV fusion inhibitors Curr. Pharm. Des. 2002, 8, 563-580
11. Wild, C. T.; Shugars, D. C.; Greenwell, T. K.; McDanal, C. B.; Matthews, T. J. Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 9770-9774
12. Cai, L.; Balogh, E.; Gochin, M. Stable extended human immunodeficiency virus type 1 gp41 coiled coil as an effective target in an assay for high-affinity fusion inhibitors Antimicrob. Agents Chemother. 2009, 53 (6) 2444-2449
13. He, Y.; Cheng, J.; Lu, H.; Li, J.; Hu, J.; Qi, Z.; Liu, Z.; Jiang, S.; Dai, Q. Potent HIV fusion inhibitors against enfuvirtide-resistant HIV-1 strains Proc. Natl. Acad. Sci. U.S.A. 2008, 105 (42) 16332-16337
14. Matthews, T.; Salgo, M.; Greenberg, M.; Chung, J.; DeMasi, R.; Bolognesi, D. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes Nat. Rev. Drug Discovery 2004, 3, 215-225
15. Ferrer, M.; Kapoor, T. M.; Strassmaier, T.; Weissenhorn, W.; Skehel, J. J.; Oprian, D.; Schreiber, S. L.; Wiley, D. C.; Harrison, S. C. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements Nat. Struct. Biol. 1999, 6 (10) 953-960
16. Gochin, M.; Zhou, G. Amphipathic properties of HIV-1 gp41 fusion inhibitors Curr. Top. Med. Chem. 2011, 11, 3022-3032
17. Jiang, S.; Tala, S. R.; Lu, H.; Abo-Dya, N. E.; Avan, I.; Gyanda, K.; Lu, L.; Katritzky, A. R.; Debnath, A. K. Design, synthesis, and biological activity of novel 5-((arylfuran/1 H -pyrrol-2-yl)methylene)-2-thioxo-3-(3- (trifluoromethyl)phenyl)thiazolidin-4-ones as HIV-1 fusion inhibitors targeting gp41 J. Med. Chem. 2011, 54, 572-579
18. Zhou, G.; Ferrer, M.; Chopra, R.; Kapoor, T. M.; Strassmaier, T.; Weissenhorn, W.; Skehel, J. J.; Oprian, D.; Schreiber, S. L.; Harrison, S. C.; Wiley, D. C. The structure of an HIV-1 specific cell entry inhibitor in complex with the HIV-1 gp41 trimeric core Bioorg. Med. Chem. 2000, 8, 2219-2238
19. Liu, S.; Boyer-Chatenet, L.; Lu, H.; Jiang, S. Rapid and automated fluorescence-linked immunosorbent assay for high throughput screening of HIV-1 fusion inhibitors targeting gp41 J. Biomol. Screening 2003, 8, 685-693
20. Jiang, S.; Lu, H.; Liu, S.; Zhao, Q.; He, Y.; Debnath, A. K. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion Antimicrob. Agents Chemother. 2004, 48 (11) 4349-4359
21. Tan, J.; Zhang, B.; Cong, X.; Yang, L.; Liu, B.; Kong, R.; Kui, Z.; Wang, C.; Hu, L. Computer-aided design, synthesis, and biological activity evaluation of potent fusion inhibitors targeting HIV-1 gp41 Med. Chem. 2011, 7, 309-316
22. Liu, K.; Lu, H.; Hou, L.; Qi, Z.; Teixeira, C.; Barbault, F.; Fan, B.; Liu, S.; Jiang, S.; Xie, L. Design, synthesis, and biological evaluation of N -carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41 J. Med. Chem. 2008, 51 (24) 7843-7854
23. Wang, Y.; Lu, H.; Zhu, Q.; Jiang, S.; Liao, Y. Structure-based design, synthesis and biological evaluation of new N-carboxyphenylpyrrole derivatives as HIV fusion inhibitors targeting gp41 Bioorg. Med. Chem. Lett. 2010, 20 (1) 189-192
24. Frey, G.; Rits-Volloch, S.; Zhang, X. Q.; Schooley, R. T.; Chen, B.; Harrison, S. C. Small molecules that bind the inner core of gp41 and inhibit HIV envelope-mediated fusion Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 13938-13943
25. Xu, Y.; Lu, H.; Kennedy, J. P.; Yan, X.; McAllister, L. A.; Yamamoto, N.; Moss, J. A.; Boldt, G. E.; Jiang, S.; Janda, K. D. Evaluation of "credit card" libraries for inhibition of HIV-1 gp41 fusogenic core formation J. Comb. Chem. 2006, 8, 531-539
26. Balogh, E.; Wu, D.; Zhou, G.; Gochin, M. NMR second site screening for structure determination of ligands bound in the hydrophobic pocket of HIV-1 gp41 J. Am. Chem. Soc. 2009, 131, 2821-2823
27. Gochin, M.; Zhou, G.; Phillips, A. H. Paramagnetic relaxation assisted docking of a small indole compound in the HIV-1 gp41 hydrophobic pocket ACS Chem. Biol. 2010, 6, 267-274
28. Wang, C.; Zhao, M.; Qiu, X.; Peng, S. The synthesis and immunosuppressive activities of steroid-urotoxin linkers Bioorg. Med. Chem. 2004, 12, 4403-4421
29. Chan, D. C.; Chutkowski, C. T.; Kim, P. S. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 15613-15617
30. Mo, H.; Konstantinidis, A. K.; Stewart, K. D.; Dekhtyar, T.; Ng, T.; Swift, K.; Matayoshi, E. D.; Kati, W.; Kohlbrenner, W.; Molla, A. Conserved residues in the coiled-coil pocket of human immunodeficiency virus type 1 gp41 are essential for viral replication and interhelical interaction Virology 2004, 329, 319-327
31. Teixeira, C.; Barbault, F.; Rebehmed, J.; Liu, K.; Xie, L.; Lu, H.; Jiang, S.; Fan, B.; Maurel, F. Molecular modeling studies of N-substituted pyrrole derivatives-Potential HIV-1 gp41 inhibitors Bioorg. Med. Chem. 2008, 16 (6) 3039-3048
32. Cai, L.; Gochin, M. A novel fluorescence intensity screening assay identifies new low-molecular-weight Inhibitors of the gp41 coiled-coil domain of human immunodeficiency virus type 1 Antimicrob. Agents Chemother. 2007, 51 (7) 2388-2395
33. Lu, L.; Tong, P.; Yu, X.; Pan, C.; Zou, P.; Chen, Y.; Jiang, S. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain Biochim. Biophys. Acta 2012, 1818, 2950-2957
34. Naito, T.; Izumi, K.; Kodama, E.; Sakagami, Y.; Kajiwara, K.; Nishikawa, H.; Watanabe, K.; Sarafianos, S. G.; Oishi, S.; Fujii, N.; Matsuoka, M. SC29EK, a peptide fusion inhibitor with enhanced α-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide Antimicrob. Agents Chemother. 2009, 53 (3) 1013-1018
35. Mink, M.; Mosier, S. M.; Janumpalli, S.; Davison, D.; Jin, L.; Melby, T.; Sista, P.; Erickson, J.; Lambert, D.; Stanfield-Oakley, S. A.; Salgo, M.; Cammack, N.; Matthews, T.; Greenberg, M. L. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro J. Virol. 2005, 79, 12447-12454
36. Wei, X.; Decker, J. M.; Liu, H.; Zhang, Z.; Arani, R. B.; Kilby, J. M.; Saag, M. S.; Wu, X.; Shaw, G. M.; Kappes, J. C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy Antimicrob. Agents Chemother. 2002, 46, 1896-1905
37. Liu, S.; Jing, W.; Cheung, B.; Lu, H.; Sun, J.; Yan, X.; Niu, J.; Farmar, J.; Wu, S.; Jiang, S. HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisims of action of anti-HIV peptides J. Biol. Chem. 2007, 282 (13) 9612-9620
38. Pang, W.; Wang, R.; Yang, L.; Liu, C.; Tien, P.; Zheng, Y. Recombinant protein of heptad-repeat HR212, a stable fusion inhibitor with potent anti-HIV action in vitro Virology 2008, 377, 80-87
39. Case, D. A.; Darden, T. A.; Cheatham, T.; Simmerling, C.; Wang, J.; Duke, R. E.; Luo, R.; Merz, K. M.; Wang, B.; Pearlman, D. A.; Crowley, M.; Brozell, S.; Tsui, V.; Gohlke, H.; Mongan, J.; Hornak, V.; Cui, G.; Beroza, P.; Schafmeister, C.; Caldwell, J. W.; Ross, W. S.; Kollman, P. A. AMBER 8; University of California: San Francisco, 2004.
40. Wexler-Cohen, Y.; Shai, Y. Demonstrating the C-terminal boundary of the HIV-1 fusion conformation in a dynamic ongoing fusion process and implication for fusion inhibition FASEB J. 2007, 21 (13) 3677-3684
41. Zhou, G.; Wu, D.; Hermel, E.; Balogh, E.; Gochin, M. Design, synthesis, and evaluation of indole compounds as novel inhibitors targeting Gp41 Bioorg. Med. Chem. Lett. 2010, 20, 1500-1503